Massive UK Study of 165,000 Patients Links Risperidone to Elevated Stroke Risk Across All Dementia Demographics

A massive study of 165,000 UK patients reveals risperidone increases stroke risk for all dementia sufferers, even those with no prior heart disease.

By: AXL Media

Published: Mar 9, 2026, 6:20 AM EDT

Source: The information in this article was sourced from Brunel University of London

Challenging the Safety Profile of Dementia’s Last-Resort Drug

New evidence from one of the largest clinical studies of its kind has sent a ripple of concern through the geriatric medical community. Researchers analyzing the health records of over 165,000 dementia patients found that risperidone, a potent antipsychotic, carries a universal risk of stroke. Previously, it was hoped that patients without a history of heart disease or prior strokes might represent a "safe" cohort for the medication. However, the data published in the British Journal of Psychiatry indicates that the risk elevation is consistent across the board, leaving doctors with no identifiable group that is immune to these cerebrovascular side effects.

The Clinical Dilemma of Managing Severe Agitation

Agitation and aggressive behavior affect approximately half of all individuals living with dementia, often reaching levels that are unmanageable through behavioral therapy alone. In these high-distress scenarios, risperidone is frequently prescribed as a last resort to ensure the safety of both the patient and their caregivers. As the only drug of its class licensed for this specific use in the UK, its role in care homes is significant. Dr. Byron Creese of Brunel University noted that while the drug’s ability to calm symptoms is documented, the lack of a "safe" patient profile forces families and physicians into increasingly difficult ethical and medical decisions.

Statistical Breakdown of Increased Stroke Incidence

The research team meticulously compared dementia patients prescribed risperidone with those who were not, covering a period from 2004 to 2023. For patients who had already suffered a stroke, the annual rate per 1,000 person-years climbed to 22.2% when taking the drug, compared to 17.7% in those who were not. Even among those with no history of stroke, the rate was notably higher at 2.9% for the risperidone group versus 2.2% for the control. Perhaps most concerning was the finding that the risk was most acute during the first 12 weeks of treatment, suggesting that even short-term use requires rigorous vigilance.